Ultragenyx Q3 revenue $98.1M (+8% YoY); reaffirms FY2023 guidance $425-450M

Ultragenyx Pharmaceutical Inc.

2023-Q3 EPS reported -$6.81 revenue$306,857,000

Total revenue $98.1M, up 8% YoY; Crysvita $74.9M, Dojolvi $16.6M.
Net loss $159.6M ($2.23/share), improved from $245.1M ($3.50/share) in Q3 2022.
Cash $524.2M at Sept 30; net $326.5M from October offering.
FY2023 guidance reaffirmed: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
Clinical: UX143 (OI) 67% fracture rate reduction; GTX-102 (Angelman) improvements; UX701 (Wilson) patients tapering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2023 results: revenue $98.1 million. Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: $98.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Higa ir@ultragenyx.com Media Jeff Blake media@ultragenyx.com Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $ 16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.